Booz Allen Hamilton Holding Corporation (BAH)

Booz Allen Hamilton is trading in the upper half of its 52-week range after a run of upgrades and a strong earnings beat, but its revenue is shrinking. The stock closed at $87.42, up 0.83% on the last session, and sits above its 20-day EMA, 50-day SMA and 200-day SMA.

Booz Allen has beaten the EPS estimate in six of its last eight reported quarters. The October 23, 2026 report delivered adjusted EPS of $1.76 against an estimate of $1.48, a beat of 18.92%, and the stock rose 6.44% in the first session afterwards. Two rating moves followed in late October: TD Cowen upgraded the stock to Buy from Hold on October 26, 2026, and Truist Securities had made the same move on October 8, 2026. Citigroup and BNP Paribas kept Neutral ratings on October 26. The upgrades are a clear shift in sentiment, though the earnings record is not a guarantee of future price gains: in three of the six beats the share price fell in the first session.

The business is growing its profits faster than its sales. Analysts expect revenue to grow only 1.4% this fiscal year. Profitability is strong by comparison: the net profit margin is 7.14%, the operating margin 8.82%, and return on equity 70.00%, against a sector median of 17.8%. Debt-to-equity of 3.78 is high, which is one reason the company's balance sheet earns only a middle score.

At a trailing P/E of 13.37, the stock trades at a discount to the sector median P/E of 34.0, which is 60.7% below it. The price-to-sales ratio of 0.94 compares with a sector median of 4.0. Insiders have been net buyers over the last 18 months: open-market purchases totalled $2.0M against $64K of sales in two transactions. The stock's beta of 0.28 against the S&P 500 means it has moved far less than the broader market, though its 30-day daily volatility is 2.51%.

The base case is that the stock keeps trading in its current uptrend while the analysts' earnings forecasts hold. Analysts expect fiscal-year EPS of $6.62, growing 1.6%, and revenue of $11.4B, growing 1.4%, which is slower than the sector median revenue growth of 11.7%. The median 12-month analyst target is $85.00, just 2.8% below the price, and the range runs from $68.00 to $140.00, so the analysts as a group see limited upside from here. A move toward the $109.10 52-week high would need revenue to return to growth, which the current figures do not show. A renewed fall in revenue, or a failure to hold the 20-day EMA at $82.89, would weaken the case. These are conditions to watch, not a forecast of direction.

Support sits at $82.89, the 20-day EMA, the nearest level below the price and the one a fall would meet first. Next is $76.86, the 50-day SMA, followed by $76.22, the 200-day SMA, which sits almost on top of it. Below that, the 52-week low of $59.50 is the deepest support in the stock's recent range. Resistance begins at the 52-week high of $109.10, which is the nearest level above the price. Analysts' targets of $85.00 (median) and $140.00 (highest) also mark price levels the market may test, though they are forecasts rather than technical levels.